Abbott gives Teva TriCor rights in 2011
Abbott Laboratories has settled U.S. patent litigation over its blockbuster cholesterol pill TriCor in a deal that allows generic versions of the treatment in early 2011. Report
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Latest Commentary
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What’s your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Scientists Find Improvement with Mesenchymal Stem Cell Signals in Animal Models of Multiple Sclerosis
- Strategy Discovered to Activate Genes that Suppress Tumors and Inhibit Cancer
- NEW DISCOVERIES ABOUT SEVERE MALARIA COULD LEAD TO NEW INTERVENTIONS
- Prosonix Extends Series B Financing Round to £17.1M
- Sue Siegel to Lead Healthymagination
- More Press Releases
Comments